Retinal Diseases
Retinal Diseases
Search
Respiratory Diseases
Respiratory Diseases
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Thinking differently could eradicate some areas of retinal disease
Retinal disease could be eradicated by thinking differently. Degenerative eye conditions can be cured with a patient-first approach, says Dr Victor Chong.
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Central Nervous System Diseases
Central Nervous System Diseases
Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
The liver and its vital connection to our overall health
How health of the liver impacts our interconnected cardiovascular, renal, metabolic system and suffering and can have several comorbidities like obesity.
Perceived burden of COPD is higher for younger patients
New global survey reveals perceived burden of disease is greater in younger people living with COPD
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund
A future without pills – could AI change the way we treat psychiatric diseases?
Dr Cornelia Dorner-Ciossek talks about how her work with smartphone tech could transform how we treat mental illness.
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Combating complex diseases with data
How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
BI 765845
Heart disease modulator
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Practical Advice
Practical advice for people with type 2 diabetes (T2D) at risk of heart disease
Cooperation with The Defeat-NCD Partnership
Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Kidney_Disease_in_Type_2_Diabetes.pdf
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Overcoming heartworm disease for homeless pets
Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
Nurjanahs Story
Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.